Drug resistant tuberculosis soars in eastern Europe
http://www.100md.com
《英国医生杂志》
Multidrug resistant tuberculosis in parts of eastern Europe and the former Soviet Union is 10 times as common as in most parts of the world, a new report from the World Health Organization said this week.
The report, which is WHO's third on drug resistant tuberculosis, contains new data obtained from the WHO/IUATLD (International Union Against Tuberculosis and Lung Disease) Global Project on Anti-Tuberculosis Drug Resistance Surveillance.
Speaking at the report's launch in London this week, Dr Paul Nunn, coordinator of tuberculosis, HIV, and drug resistance at the Stop TB department of WHO, said: "We see about nine million cases worldwide every year and about two million deaths."
He said: "This report . . . covers 77 geographic settings, most of which are countries—except in certain instances like China, where several settings are in one country. Thirty nine of the settings are new, and 67 657 cases were tested.
"It was found that multidrug resistance in parts of eastern Europe and the former Soviet Union was 10 times what it was in the rest of the world, with rates as high as 14% in new patients."
On the link between tuberculosis and HIV, Dr Nunn said: "In the former Soviet Union, about 1.5 million people are HIV positive, and the rate of rise is faster than ever before."
He added: "We are calling for expansion of DOTS , increased investment in DOTS-Plus, increased investment in laboratory networks, and increased investment in drug resistance surveillance. This report covers only 20% of the world's population."
Dr Mario Raviglione, director of the Stop TB department of WHO, said: "The best way to control TB is the DOTS approach." He said: "TB drug resistance is an urgent public health issue . . . It is in the interest of every country to support rapid scale-up of TB control if we are to overcome multidrug resistant TB. Passport control will not halt drug resistance; investment in global TB prevention will."
Dr Paul Sommerfield, founder and chairman of TB Alert UK, said: "The prevalence of multidrug resistant TB in the UK now is between 1% and 1.5%." However, he added: "The most important intervention is a worldwide effort."
Multidrug resistant tuberculosis occurs when patients no longer benefit from treatment with the two main drugs for tuberculosis, isoniazid and rifampicin. It can arise due to poor adherence to treatment, inappropriate prescription, irregular drug supply, or poor drug quality. It can be fatal if untreated, and the cost of treatment is 100 times more than that for treating non-resistant tuberculosis. Treatment takes the form of second line drugs such as cycloserine and capreomycin. In view of the cost of these drugs, WHO has set up a "green light" committee that facilitates access to these drugs at prices as low as 99% under the market price.(BMJ Chibuzo Odigwe)
婵犵數鍎戠徊钘壝洪悩璇茬婵犻潧娲ら閬嶆煕濞戝崬鏋ゆい鈺冨厴閺屾稑鈽夐崡鐐差潾闁哄鏅滃Λ鍐蓟濞戞ǚ鏋庨煫鍥ㄦ尨閸嬫挻绂掔€ｎ亞鍔﹀銈嗗坊閸嬫捇鏌涢悩宕囥€掓俊鍙夊姇閳规垿宕堕埞鐐亙闁诲骸绠嶉崕鍗炍涘☉銏犵劦妞ゆ帒顦悘锔筋殽閻愬樊鍎旀鐐叉喘椤㈡棃宕ㄩ鐐靛搸婵犵數鍋犻幓顏嗗緤閹灐娲箣閻樺吀绗夐梺鎸庣箓閹峰宕甸崼婢棃鏁傜粵瀣妼闂佸摜鍋為幐鎶藉蓟閺囥垹骞㈤柡鍥╁Т婵′粙鏌ｉ姀鈺佺仩缂傚秴锕獮濠囨晸閻樿尙鐤€濡炪倖鎸鹃崑鐔哥閹扮増鈷戦柛锔诲帎閻熸噴娲Χ閸ヮ煈娼熼梺鍐叉惈閹冲氦绻氶梻浣呵归張顒傜矙閹烘鍊垫い鏂垮⒔绾惧ジ鏌￠崘銊モ偓绋挎毄濠电姭鎷冮崟鍨杹閻庢鍠栭悥鐓庣暦濮椻偓婵℃瓕顦抽柛鎾村灦缁绘稓鈧稒岣块惌濠偽旈悩鍙夋喐闁轰緡鍣ｉ、鏇㈡晜閽樺鈧稑鈹戦敍鍕粶濠⒀呮櫕缁瑦绻濋崶銊у幐婵犮垼娉涢敃銈夊汲閺囩喐鍙忛柣鐔煎亰濡偓闂佽桨绀佺粔鎾偩濠靛绀冩い顓熷灣閹寸兘姊绘担绛嬪殐闁哥姵鎹囧畷婵婄疀濞戣鲸鏅ｇ紓鍌欑劍宀ｅ潡鍩㈤弮鍫熺厽闁瑰鍎戞笟娑㈡煕閺傚灝鏆ｉ柡宀嬬節瀹曟帒顫濋鐘靛幀缂傚倷鐒﹂〃鍛此囬柆宥呯劦妞ゆ帒鍠氬ḿ鎰磼椤旇偐绠婚柨婵堝仱閺佸啴宕掑鍗炴憢闂佽崵濞€缂傛艾鈻嶉敐鍥╃煋闁割煈鍠撻埀顒佸笒椤繈顢橀悩顐ｎ潔闂備線娼уú銈吤洪妸鈺佺劦妞ゆ帒鍋嗛弨鐗堢箾婢跺娲寸€规洏鍨芥俊鍫曞炊閵娿儺浼曢柣鐔哥矌婢ф鏁Δ鍜冪稏濠㈣埖鍔栭崑锝夋煕閵夘垰顩☉鎾瑰皺缁辨帗娼忛妸褏鐣奸梺褰掝棑婵炩偓闁诡喗绮撻幐濠冨緞婢跺瞼姊炬繝鐢靛仜椤曨厽鎱ㄦィ鍐ㄦ槬闁哄稁鍘奸崹鍌炴煏婵炵偓娅嗛柛瀣ㄥ妼闇夐柨婵嗘噹閺嗙喐淇婇姘卞ⅵ婵﹥妞介、鏇㈡晲閸℃瑦顓婚梻浣虹帛閹碱偆鎹㈠┑瀣祦閻庯綆鍠栫粻锝嗙節婵犲倸顏柟鏋姂濮婃椽骞愭惔锝傛闂佸搫鐗滈崜鐔风暦閻熸壋鍫柛鏇ㄥ弾濞村嫬顪冮妶鍡楃瑐闁绘帪绠撳鎶筋敂閸喓鍘遍梺鐟版惈缁夋潙鐣甸崱娑欑厓鐟滄粓宕滃顒夋僵闁靛ň鏅滈崑鍌炴煥閻斿搫孝閻熸瑱绠撻獮鏍箹椤撶偟浠紓浣插亾濠㈣泛鈯曡ぐ鎺戠闁稿繗鍋愬▓銈夋⒑缂佹ḿ绠栭柣鈺婂灠閻ｇ兘鏁撻悩鑼槰闂佽偐鈷堥崜姘额敊閹达附鈷戦悹鍥ｂ偓铏亖闂佸憡鏌ㄦ鎼佸煝閹捐绠ｉ柣鎰綑椤庢挸鈹戦悩璇у伐闁哥噥鍨堕獮鍡涘磼濮ｎ厼缍婇幃鈺呭箵閹烘繂濡锋繝鐢靛Л閸嬫捇鏌熷▓鍨灓缁鹃箖绠栭弻鐔衡偓鐢登瑰暩閻熸粎澧楅悡锟犲蓟濞戙垹绠抽柡鍌氱氨閺嬪懎鈹戦悙鍙夊櫣闂佸府绲炬穱濠囧箻椤旇姤娅㈤梺璺ㄥ櫐閹凤拷The report, which is WHO's third on drug resistant tuberculosis, contains new data obtained from the WHO/IUATLD (International Union Against Tuberculosis and Lung Disease) Global Project on Anti-Tuberculosis Drug Resistance Surveillance.
Speaking at the report's launch in London this week, Dr Paul Nunn, coordinator of tuberculosis, HIV, and drug resistance at the Stop TB department of WHO, said: "We see about nine million cases worldwide every year and about two million deaths."
He said: "This report . . . covers 77 geographic settings, most of which are countries—except in certain instances like China, where several settings are in one country. Thirty nine of the settings are new, and 67 657 cases were tested.
"It was found that multidrug resistance in parts of eastern Europe and the former Soviet Union was 10 times what it was in the rest of the world, with rates as high as 14% in new patients."
On the link between tuberculosis and HIV, Dr Nunn said: "In the former Soviet Union, about 1.5 million people are HIV positive, and the rate of rise is faster than ever before."
He added: "We are calling for expansion of DOTS , increased investment in DOTS-Plus, increased investment in laboratory networks, and increased investment in drug resistance surveillance. This report covers only 20% of the world's population."
Dr Mario Raviglione, director of the Stop TB department of WHO, said: "The best way to control TB is the DOTS approach." He said: "TB drug resistance is an urgent public health issue . . . It is in the interest of every country to support rapid scale-up of TB control if we are to overcome multidrug resistant TB. Passport control will not halt drug resistance; investment in global TB prevention will."
Dr Paul Sommerfield, founder and chairman of TB Alert UK, said: "The prevalence of multidrug resistant TB in the UK now is between 1% and 1.5%." However, he added: "The most important intervention is a worldwide effort."
Multidrug resistant tuberculosis occurs when patients no longer benefit from treatment with the two main drugs for tuberculosis, isoniazid and rifampicin. It can arise due to poor adherence to treatment, inappropriate prescription, irregular drug supply, or poor drug quality. It can be fatal if untreated, and the cost of treatment is 100 times more than that for treating non-resistant tuberculosis. Treatment takes the form of second line drugs such as cycloserine and capreomycin. In view of the cost of these drugs, WHO has set up a "green light" committee that facilitates access to these drugs at prices as low as 99% under the market price.(BMJ Chibuzo Odigwe)